Previous 10 | Next 10 |
Shares of cancer specialist Exelixis (NASDAQ: EXEL) dropped by 12.6% in October, according to data from S&P Global Market Intelligence . Why did investors hit the exits last month? Despite a strong month for biotech stocks in general, Exelixis' shares were essentia...
It might be hard to believe, but in just seven weeks we'll be saying our goodbyes to 2019. Although investors have endured a couple of short-lived rough patches, it's been an exceptionally strong year for the stock market. The broad-based S&P 500 is up 23%, the iconic Dow J...
-- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Shares of Exelixis (NASDAQ: EXEL) are down 10% at 1:15 p.m. EDT following the release of third-quarter earnings yesterday after the bell. Product revenue, which mostly comes from sales of Exelixis' liver and kidney cancer drug Cabometyx, came in at $191.8 million, a 17.7% year-over-year i...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q3 2019 Earnings Call Oct 30, 2019 , 5:00 p.m. ET Operator Continue reading
Exelixis, Inc. (EXEL) Q3 2019 Results Earnings Conference Call October 30, 2019, 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - Chief Financial Officer P.J. Haley - Senior Vice Pr...
Exelixis (NASDAQ: EXEL ): Q3 Non-GAAP EPS of $0.34 beats by $0.15 ; GAAP EPS of $0.31 beats by $0.12 . Revenue of $271.7M (+20.5% Y/Y) beats by $43.53M . Press Release More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news,
- Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results fo...
Despite starting the year off strong, biotech stocks have had a rough summer. The recent weakness in the biotech sector is causing biotech exchange-traded funds (ETFs) like the VanEck Vectors Biotech ETF (BBH), the iShares NASDAQ Biotechnology ETF (IBB), and the SPDR S&P Bio...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...